Volume 63, Issue 4, Pages (April 2013)

Slides:

Advertisements

Similar presentations

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Advertisements

Volume 50, Issue 5, Pages (November 2006)

Volume 66, Issue 6, Pages (December 2014)

European Urology Focus

Volume 58, Issue 1, Pages (July 2010)

Volume 60, Issue 2, Pages (August 2011)

Volume 67, Issue 5, Pages (May 2015)

Potential and Limitations of Diffusion-Weighted Magnetic Resonance Imaging in Kidney, Prostate, and Bladder Cancer Including Pelvic Lymph Node Staging:

Volume 66, Issue 1, Pages (July 2014)

Volume 61, Issue 5, Pages (May 2012)

Volume 50, Issue 5, Pages (November 2006)

Lack of KRAS and BRAF Mutation in Renal Cell Carcinoma

Volume 51, Issue 4, Pages (April 2007)

Volume 51, Issue 3, Pages (March 2007)

Volume 69, Issue 1, Pages 4-6 (January 2016)

Histologic Grading of Noninvasive Papillary Urothelial Neoplasms

Volume 53, Issue 5, Pages (May 2008)

Volume 71, Issue 6, Pages e171-e172 (June 2017)

Volume 72, Issue 5, Pages (November 2017)

Volume 51, Issue 5, Pages (May 2007)

Volume 61, Issue 4, Pages (April 2012)

Volume 59, Issue 2, Pages (February 2011)

Volume 63, Issue 1, Pages (January 2013)

Treatment of Advanced and Metastatic Renal Cancer: A Revolution?

Bladder Cancer: A Major Public Health Issue

Nomograms for Bladder Cancer

Precystectomy Nomogram for Prediction of Advanced Bladder Cancer Stage

The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.

Volume 51, Issue 5, Pages (May 2007)

Volume 61, Issue 5, Pages (May 2012)

Volume 61, Issue 4, Pages (April 2012)

Volume 60, Issue 5, Pages (November 2011)

CEACAM1: A Novel Urinary Marker for Bladder Cancer Detection

Volume 68, Issue 1, Pages (July 2015)

Volume 61, Issue 6, Pages (June 2012)

Volume 63, Issue 5, Pages (May 2013)

Volume 69, Issue 3, Pages (March 2016)

Volume 52, Issue 3, Pages (September 2007)

Volume 64, Issue 3, Pages (September 2013)

International Society of Urological Pathology Grading and Other Prognostic Factors for Renal Neoplasia Brett Delahunt, John R. Srigley, Lars Egevad,

Volume 56, Issue 6, Pages (December 2009)

Volume 53, Issue 4, Pages (April 2008)

Nat. Rev. Urol. doi: /nrurol

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 53, Issue 6, Pages (June 2008)

Volume 66, Issue 6, Pages (December 2014)

Volume 66, Issue 6, Pages (December 2014)

Long-term Cancer-specific Survival in Patients with High-risk, Non–muscle-invasive Bladder Cancer and Tumour Progression: A Systematic Review Sven van.

Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia

The Economic Costs of Overactive Bladder in Germany

Karl-Dietrich Sievert, Bastian Amend, Arnulf Stenzl European Urology

Volume 53, Issue 1, Pages (January 2008)

Volume 69, Issue 6, Pages (June 2016)

Volume 62, Issue 3, Pages (September 2012)

Volume 50, Issue 5, Pages (November 2006)

Volume 71, Issue 5, Pages (May 2017)

Testicular Cancer Variations in Time and Space in Europe

The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic.

Prognostic Impact of Comorbidity in Patients with Bladder Cancer

European Urology is “Your” Journal

Jonathan S. Brajtbord, Michael S. Leapman, Matthew R. Cooperberg

Volume 55, Issue 6, Pages (June 2009)

Economic Burden of Bladder Cancer Across the European Union

Georges-Pascal Haber, Sebastien Crouzet, Inderbir S. Gill

Volume 52, Issue 4, Pages (October 2007)

Early Single-Instillation Chemotherapy Has No Real Benefit and Should Be Abandoned in Non–Muscle-Invasive Bladder Cancer Sten Holmäng European Urology.

Volume 52, Issue 1, Pages (July 2007)

Volume 54, Issue 1, Pages (July 2008)

Volume 51, Issue 5, Pages (May 2007)

Maximilian Burger, Ashish M. Kamat, David McConkey

Presentation transcript:

Volume 63, Issue 4, Pages 739-744 (April 2013) Prognostic Value of Perinodal Lymphovascular Invasion Following Radical Cystectomy for Lymph Node–positive Urothelial Carcinoma Hans-Martin Fritsche, Matthias May, Stefan Denzinger, Wolfgang Otto, Sabine Siegert, Christian Giedl, Johannes Giedl, Fabian Eder, Abbas Agaimy, Vladimir Novotny, Manfred Wirth, Christian Stief, Sabine Brookman-May, Ferdinand Hofstädter, Michael Gierth, Atiqullah Aziz, Arkadius Kocot, Hubertus Riedmiller, Patrick J. Bastian, Marieta Toma, Wolf F. Wieland, Arndt Hartmann, Maximilian Burger European Urology Volume 63, Issue 4, Pages 739-744 (April 2013) DOI: 10.1016/j.eururo.2012.09.053 Copyright © 2012 European Association of Urology Terms and Conditions

Fig. 1 Extranodal extension of urothelial carcinoma (haematoxylin and eosin, ×100). Note the clear invasion of the tumour cells (asterisks) in the perinodal tissue with adipocytes (arrowheads) and large blood vessels (arrow). European Urology 2013 63, 739-744DOI: (10.1016/j.eururo.2012.09.053) Copyright © 2012 European Association of Urology Terms and Conditions

Fig. 2 Perinodal lymphovascular invasion with tumour cells (arrow) within a lymphatic vessel with clearly visible endothelial lining (arrowheads); note the focal adherence to the endothelial cells (asterisks) (haematoxylin and eosin, ×200). European Urology 2013 63, 739-744DOI: (10.1016/j.eururo.2012.09.053) Copyright © 2012 European Association of Urology Terms and Conditions

Fig. 3 Cancer-specific survival in 158 lymph node–positive patients after radical cystectomy for urothelial carcinoma of the bladder, stratified by absence or presence of perinodal lymphovascular invasion. pnLVI=perinodal lymphovascular invasion. European Urology 2013 63, 739-744DOI: (10.1016/j.eururo.2012.09.053) Copyright © 2012 European Association of Urology Terms and Conditions

Fig. 4 Cancer-specific survival in 158 lymph node–positive patients after radical cystectomy for urothelial carcinoma of the bladder, stratified by absence or presence of perinodal lymphovascular invasion (pnLVI) in combination with pT category. Low risk: pnLVI absent and ≤pT2; intermediate risk: pnLVI present or ≥pT3; high risk: pnLVI present and ≥pT3. LR=low risk; IR=intermediate risk; HR=high risk. European Urology 2013 63, 739-744DOI: (10.1016/j.eururo.2012.09.053) Copyright © 2012 European Association of Urology Terms and Conditions